-
Mashup Score: 74Novartis calls time on Tim3 drug sabatolimab in MDS - 3 month(s) ago
Novartis ends development of Tim3 antibody sabatolimab in myelodysplastic syndromes after failed phase 3 trial.
Source: pharmaphorum.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 9Investigating Hypomethylating Agents for Myelodysplastic Syndromes With Amer Zeidan - 3 month(s) ago
Recently, at the American Society of Hematology (ASH) Annual Meeting, Amer Zeidan, MBBS, MHS, the Interim Chief of Hematologic Malignancies Division at the Y…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 78Vitamin B5 and succinyl-CoA improve ineffective erythropoiesis in SF3B1-mutated myelodysplasia - 3 month(s) ago
Vitamin B5 and succinyl-CoA compensate aberrant COASY splicing in SF3B1mut myelodysplasia, rescuing heme depletion and ineffective erythropoiesis.
Source: www.science.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 29Join me! | Smarter. Stronger. Together. Optimizing MDS Care and Addressing Health Disparities Through Education of Providers, Patients, and Caregivers - 4 month(s) ago
Slides from Amer Zeidan, MBBS, highlighting some of the most important developments in optimizing the management of myelodysplastic syndromes, including patient survey results, clinical trial findings and their implications for clinical practice, from Clinical Care Options (CCO)
Source: clinicaloptions.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7
The authors concluded that the data support consideration of the oral regimen of decitabine and cedazuridine to reduce the treatment burden associated with intraveous or subcutaneous hypomethylating agents in patients with myelodysplastic syndromes (MDS).
Source: www.ajmc.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 98
The DNA methyltransferase inhibitors azacitidine and decitabine for individuals with myelodysplastic syndromes or chronic myelomonocytic leukaemia areā¦
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 21
Oral decitabineācedazuridine was pharmacologically and pharmacodynamically equivalent to intravenous decitabine. The results support use of oral decitabineācedazuridine as a safe and effective alternative to intravenous decitabine for treatment of individuals with myelodysplastic syndromes or chronic myelomonocytic leukaemia.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet-
NEW: results from the phase 3, crossover, ASCERTAIN trial assessing the safety and pharmacokinetics of oral decitabine plus cedazuridine versus intravenous decitabine in patients with myelodysplastic syndromes or chronic myelomonocytic leukaemia #MDSsm https://t.co/p7x4w81CX6 https://t.co/560MYmTWMB
-
-
Mashup Score: 1Oral decitabine plus cedazuridine versus intravenous decitabine - 4 month(s) ago
Two DNA methyltransferase inhibitors have been available for parenteral treatment of people with myelodysplastic syndromes and chronic myelomonocytic leukaemia for several decades. Treatment with either decitabine1 or azacitidine2 requires frequent visits to hospitals or care units. These DNA methyltransferase inhibitors are effective in about 50% of people with higher risk (as defined in the standard International Prognostic Scoring System) myelodysplastic syndromes or chronic myelomonocytic leukaemia, with short response durations and usual prolongation of survival of less than 1 year.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 96
The DNA methyltransferase inhibitors azacitidine and decitabine for individuals with myelodysplastic syndromes or chronic myelomonocytic leukaemia areā¦
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Is there a path forward for immunotherapy in patients with myelodysplastic syndromes? - 5 month(s) ago
Immunotherapy in some forms is a well established treatment in patients with myelodysplastic syndromes. Allogeneic haematopoietic stem-cell transplantation (HSCT) has long been an efficacious treatment for high-risk myelodysplastic syndromes, and it is the only option that allows durable disease control and a potential cure for some patients.1 However, allogeneic HSCT is not suitable for many patients due to frailty or comorbidities. For these patients, the enduring standard of care therapy is treatment with a hypomethylating agent.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
Discouraging news today: #MDSsm sabatolimab+azacitidine STIMULUS-MDS2 trial was negative (no OS benefit vs aza alone.) It has been so long since there was good news in HR MDS. If venetoclax+HMA trial is negative will Pharma give up on HR-MDS as too hard?šhttps://t.co/gn9Nwp8TzR